Astrana Health, Inc. (ASTH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Astrana Health, Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company operating through three segments: Care Partners, Care Delivery, and Care Enablement. As of June 30, 2025, the company managed over 1.0 million patients through 21 independent risk-bearing organizations. A significant subsequent event occurred on July 1, 2025, with the completion of the acquisition of certain assets and businesses of Prospect Medical Holdings, Inc. ("Prospect Transaction"), expanding the network to over 20,000 providers and 1.6 million patients.
Key Financial Metrics (Six Months Ended June 30, 2025)
- Revenue: $1.275 billion (up 43% year-over-year), driven primarily by a $389.6 million increase in capitation revenue.
- Net Income: $16.4 million total; $16.1 million attributable to Astrana Health, Inc. (down 53% year-over-year).
- Operating Income: $40.9 million (down 32% year-over-year).
- Adjusted EBITDA: $84.5 million (down 6% year-over-year); Adjusted EBITDA margin was 7%.
- Cash Flow: Net cash provided by operating activities was $107.5 million (up 269% year-over-year).
- Liquidity: Cash and cash equivalents totaled $339.7 million as of June 30, 2025. Working capital was $269.4 million.
- Debt: Total debt balance was $418.8 million. The company maintains a credit facility with a $300 million revolver, $250 million term loan, and a $745 million delayed draw term loan (DDTL A).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $384.6 million compared to the prior year period. Capitation revenue grew 48% due to recent acquisitions and enrollees transitioning to full risk.
- Expense Increases: Cost of services rose 51% to $1.126 billion, commensurate with revenue growth and increased participation in value-based Medicare FFS models. General and administrative expenses increased 27% to $94.6 million, driven by stock-based compensation and transaction costs related to the Prospect acquisition.
- Profitability Decline: Despite revenue growth, net income attributable to the company declined significantly due to higher operating costs, increased interest expense (partially offset by lower rates), and non-recurring transaction costs.
- Segment Performance: The Care Partners segment saw revenue increase 46% and operating income increase 12%. The Care Delivery segment reported an operating loss of $0.96 million for the six months, compared to income of $1.6 million in the prior year, due to expenses from new clinic locations.
Guidance, Outlook, and Risks
- Outlook: Management believes the company has sufficient liquidity to fund operations for at least the next 12 months. The company is focused on integrating the Prospect acquisition and navigating regulatory changes.
- Regulatory Risks: The "One Big Beautiful Bill Act" (OBBBA), signed July 4, 2025, introduces Medicaid work-requirement pilots and tighter provider-tax rules. Management views these as manageable headwinds but notes potential risks to patient population and revenues.
- Acquisition Risks: On July 7, 2025, certain Prospect asset seller entities filed for Chapter 11 bankruptcy. While the asset sale structure aims to shield Astrana from liabilities, there is a risk of incurring additional costs to protect business interests if sellers breach contractual obligations.
- Debt Covenants: The company must maintain a maximum consolidated total net leverage ratio of 5.00 to 1.00 (until March 2027) and a minimum interest coverage ratio of 2.50 to 1.00.
Investor Verification Checklist
- Verify the integration progress and financial impact of the Prospect Transaction (closed July 1, 2025) in future filings, as pro forma data is not yet available.
- Monitor the impact of the OBBBA legislation on Medicaid enrollment and provider tax revenues, particularly for the newly acquired Foothill Regional Medical Center.
- Assess the financial implications of the bankruptcy filing by Prospect seller entities and any potential costs absorbed by Astrana.
- Review the medical liabilities balance, which increased to $287.7 million, and the associated claims payment trends.
- Track the utilization of the Delayed Draw Term Loan (DDTL A), of which $707.3 million was drawn to finance the Prospect acquisition.